Ugly Top x 2And according to Heiken-Ashi candles, this is still in a downtrend.
This has broken the neckline of the 2nd head and shoulders top. You can get a guesstimate of where a head and shoulders top may go by drawing a line from the head to the neckline, then projecting it downward from the neckline.
EW broke the neckline of the first bad/ugly top but did not fall far before resuming an uptrend again. I am not sure if this will be a regular occurrence anymore in our current market like if has been a for the last few years. But who knows?
Earnings Miss noted recently. As of late those do seem to matter, and can linger for a bit longer than they would have in the last few years
I like this stock but am watching for now. Earnings 3-27 AMC.
MKT cap 65.5 Billion. PE 40.94 (could be lower for this sector) Short interest less than 1%. EPS 2.56. Revenue is growing quarter after quarter
Oversold on daily RSI. Not oversold on weekly RSI but closing in on it and is by no mean oversold or monthly RSI, but is not overbought either. Securities can remain oversold for extended periods of time especially if there is a lot of supply at that level.
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient’s heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
If you can’t spot the sucker 30 minutes after sitting down at a table,
it’s probably you.
EWL trade ideas
EW - Perfect chart?EW - Earnings next week, but I like the chart so much, I may hold through. If it moves up enough before earnings to sell half at a nice profit, I may do that.
I really like the chart. It's got positive longer term momentum, plus it's gaining strength from a shorter term VWAP perspective.
EW - DOUBLE BOTTOM PATTTERNNYSE:EW
EDWARDS LIFESCIENCES CORP forming a double bottom pattern and reached buy point levels. Per Stock Conquer putting in a 5% stop . All indicators recently made a move from oversold levels with the MACD recently confirming off of oversold levels where the signal line has crossed. EW price consensus across analysist puts this stock at $91.50 to $105. We will be happy to take profits off the table at those levels.
Cup and HandleEW got caught in a bearish Rising wedge, pulled back and appears to have recovered
Handle low changed though due to pull back from RW
NV is high
R will most likely be a prior high of 87.79 before it fell from RW pattern
This stock split a while back and is a long term uptrend
Not a recommendation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral valve diseases, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Cup and HandleThis stock split a while back and shares went down post split. Was over 200 when split occurred. I am wondering if same will happen when TSLA splits? Just a tought
EW appears to be at hard R right now . I am watching.
Not a recommendation. Monthly candle looks good. NV high Short is low. No rising wedges noted
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral valve diseases, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Edwards Lifesciences Corp. Bullish Upgrade Citi analyst Joanne Wuensch initiated coverage of Edwards Lifesciences with a Buy rating and $252 price target. The analyst said the focus of the company is on their TAVR and TMTT franchises -- which she called large, growing market opportunities -- noting that the TAVR market is expected to increase to reach $7B in 2024 from $4B today and the TMTT market expected to reach $3B in 2024 from $1B estimated in 2021.
thefly.com
Average analysts price target $262 | Overweight
Company profile
Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. Its portfolio includes technologies designed for nonsurgical replacement of heart valves. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The Critical Care portfolio products through hemodynamic monitoring system measures a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.